Cargando…
Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists
PURPOSE: We examined the effect of olodaterol on the risk of myocardial ischaemia, cardiac arrhythmia, and all‐cause mortality compared with use of other long‐acting beta2‐agonists (LABAs). Channelling bias was also explored. METHODS: This Danish population‐based cohort study used data linked from r...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545725/ https://www.ncbi.nlm.nih.gov/pubmed/35320605 http://dx.doi.org/10.1002/pds.5432 |
_version_ | 1784804883715588096 |
---|---|
author | Rebordosa, Cristina Farkas, Dóra Körmendiné Montonen, Jukka Laugesen, Kristina Voss, Florian Aguado, Jaume Bothner, Ulrich Rothman, Kenneth J. Zint, Kristina Mines, Daniel Ehrenstein, Vera |
author_facet | Rebordosa, Cristina Farkas, Dóra Körmendiné Montonen, Jukka Laugesen, Kristina Voss, Florian Aguado, Jaume Bothner, Ulrich Rothman, Kenneth J. Zint, Kristina Mines, Daniel Ehrenstein, Vera |
author_sort | Rebordosa, Cristina |
collection | PubMed |
description | PURPOSE: We examined the effect of olodaterol on the risk of myocardial ischaemia, cardiac arrhythmia, and all‐cause mortality compared with use of other long‐acting beta2‐agonists (LABAs). Channelling bias was also explored. METHODS: This Danish population‐based cohort study used data linked from registries of hospital diagnoses, outpatient dispensings, and deaths. It included patients (aged ≥40 years) with a diagnosis of chronic obstructive pulmonary disease (COPD) who initiated olodaterol or another LABA. Using matching and propensity score (PS) stratification, we calculated adjusted incidence rate ratios (IRRs) using Poisson regression, followed by several additional analyses to evaluate and control channelling bias. RESULTS: The IRRs of cardiac arrhythmias or myocardial ischaemia among users of olodaterol (n = 14 239) compared to users of other LABAs (n = 51 167) ranged from 0.96 to 1.65 in various analyses, although some estimates had low precision. Initial analysis suggested an increased risk for death with olodaterol compared with other LABAs (IRR, 1.63; 95% CI, 1.44–1.84). Because olodaterol prescribing was associated with COPD severity, the mortality association was attenuated by using different methods of tighter confounding control: the IRRs were 1.26 (95% CI, 0.97–1.64) among LABA‐naïve LABA/LAMA users without recent COPD hospitalisation; 1.27 (95% CI, 1.03–1.57) in a population with additional trimming from the tails of the PS distribution; and 1.32 (95% CI, 1.19–1.48) after applying overlap‐weights analysis. CONCLUSIONS: Olodaterol users had a similar risk for cardiac arrhythmias or myocardial ischaemia as other LABA users. The observed excess all‐cause mortality associated with olodaterol use could be due to uncontrolled channelling bias. |
format | Online Article Text |
id | pubmed-9545725 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95457252022-10-14 Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists Rebordosa, Cristina Farkas, Dóra Körmendiné Montonen, Jukka Laugesen, Kristina Voss, Florian Aguado, Jaume Bothner, Ulrich Rothman, Kenneth J. Zint, Kristina Mines, Daniel Ehrenstein, Vera Pharmacoepidemiol Drug Saf Original Articles PURPOSE: We examined the effect of olodaterol on the risk of myocardial ischaemia, cardiac arrhythmia, and all‐cause mortality compared with use of other long‐acting beta2‐agonists (LABAs). Channelling bias was also explored. METHODS: This Danish population‐based cohort study used data linked from registries of hospital diagnoses, outpatient dispensings, and deaths. It included patients (aged ≥40 years) with a diagnosis of chronic obstructive pulmonary disease (COPD) who initiated olodaterol or another LABA. Using matching and propensity score (PS) stratification, we calculated adjusted incidence rate ratios (IRRs) using Poisson regression, followed by several additional analyses to evaluate and control channelling bias. RESULTS: The IRRs of cardiac arrhythmias or myocardial ischaemia among users of olodaterol (n = 14 239) compared to users of other LABAs (n = 51 167) ranged from 0.96 to 1.65 in various analyses, although some estimates had low precision. Initial analysis suggested an increased risk for death with olodaterol compared with other LABAs (IRR, 1.63; 95% CI, 1.44–1.84). Because olodaterol prescribing was associated with COPD severity, the mortality association was attenuated by using different methods of tighter confounding control: the IRRs were 1.26 (95% CI, 0.97–1.64) among LABA‐naïve LABA/LAMA users without recent COPD hospitalisation; 1.27 (95% CI, 1.03–1.57) in a population with additional trimming from the tails of the PS distribution; and 1.32 (95% CI, 1.19–1.48) after applying overlap‐weights analysis. CONCLUSIONS: Olodaterol users had a similar risk for cardiac arrhythmias or myocardial ischaemia as other LABA users. The observed excess all‐cause mortality associated with olodaterol use could be due to uncontrolled channelling bias. John Wiley & Sons, Inc. 2022-05-13 2022-08 /pmc/articles/PMC9545725/ /pubmed/35320605 http://dx.doi.org/10.1002/pds.5432 Text en © 2022 Boehringer Ingelheim International GmbH. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Rebordosa, Cristina Farkas, Dóra Körmendiné Montonen, Jukka Laugesen, Kristina Voss, Florian Aguado, Jaume Bothner, Ulrich Rothman, Kenneth J. Zint, Kristina Mines, Daniel Ehrenstein, Vera Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists |
title | Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists |
title_full | Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists |
title_fullStr | Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists |
title_full_unstemmed | Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists |
title_short | Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists |
title_sort | cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545725/ https://www.ncbi.nlm.nih.gov/pubmed/35320605 http://dx.doi.org/10.1002/pds.5432 |
work_keys_str_mv | AT rebordosacristina cardiovasculareventsandallcausemortalityinpatientswithchronicobstructivepulmonarydiseaseusingolodaterolandotherlongactingbeta2agonists AT farkasdorakormendine cardiovasculareventsandallcausemortalityinpatientswithchronicobstructivepulmonarydiseaseusingolodaterolandotherlongactingbeta2agonists AT montonenjukka cardiovasculareventsandallcausemortalityinpatientswithchronicobstructivepulmonarydiseaseusingolodaterolandotherlongactingbeta2agonists AT laugesenkristina cardiovasculareventsandallcausemortalityinpatientswithchronicobstructivepulmonarydiseaseusingolodaterolandotherlongactingbeta2agonists AT vossflorian cardiovasculareventsandallcausemortalityinpatientswithchronicobstructivepulmonarydiseaseusingolodaterolandotherlongactingbeta2agonists AT aguadojaume cardiovasculareventsandallcausemortalityinpatientswithchronicobstructivepulmonarydiseaseusingolodaterolandotherlongactingbeta2agonists AT bothnerulrich cardiovasculareventsandallcausemortalityinpatientswithchronicobstructivepulmonarydiseaseusingolodaterolandotherlongactingbeta2agonists AT rothmankennethj cardiovasculareventsandallcausemortalityinpatientswithchronicobstructivepulmonarydiseaseusingolodaterolandotherlongactingbeta2agonists AT zintkristina cardiovasculareventsandallcausemortalityinpatientswithchronicobstructivepulmonarydiseaseusingolodaterolandotherlongactingbeta2agonists AT minesdaniel cardiovasculareventsandallcausemortalityinpatientswithchronicobstructivepulmonarydiseaseusingolodaterolandotherlongactingbeta2agonists AT ehrensteinvera cardiovasculareventsandallcausemortalityinpatientswithchronicobstructivepulmonarydiseaseusingolodaterolandotherlongactingbeta2agonists |